Connect with us

BioPharma

Humbl Inc (OTCMKTS: HMBL) Major Comeback Brewing as Mobile Payments Operator Looks to Up List & Releases Latest “HUMBL Pay” Upgrades

Published

on

Humbl Inc (OTCMKTS: HMBL) is coiled tight trading just over established support levels on heavy interest trading $2.3 million in dollar volume on Wednesday alone; a slow day for Humbl. The stock has huge support from investors and a massive following who see big things happening here. The Company continues to make progress recently releasing the newest release of the “HUMBL Pay” mobile wallet, including the latest upgrades to its Peer-to-Peer (P2P) functionalities, and additional features that simplify the management of digital assets and blockchain functionality. The release is now available on the Apple App Store and Google Play Store. 

HMBL recently brought back George Sharp as Capital Markets Advisor. Mr. Sharp will shepherd HUMBL through an imminent application with OTC Markets for an advancement to the OTCQB tier and then towards an application to the NASDAQ Stock Market. In furtherance of these milestones, the company will file audited financials with the SEC beginning with the yearend statement for 2021. HMBL was one of the biggest runners of early 2021 when the stock skyrocketed shortly after the name and ticker symbol change from TSNP. George Sharp is a stock whizz with anything he touched turning to gold and HMBL was the biggest runner of them all going from sub pennies to multi dollars. There are plenty of coming catalysts including the next App updates, NFT, Tickeri, music beta test and the anticipated coming OTCQB uplist. 

Humbl Inc (OTCMKTS: HMBL) is a consumer blockchain company working to simplify blockchain use cases across verticals like mobile payments, ticketing, NFTs and real estate. HUMBL is comprised of team members from companies like Western Union, Moneygram, Visa, American Express, Epson, Microsoft, Facebook and Qualcomm and was recently named a Forbes “Rising Startups to Watch” in June 2020 for recognizing the “major gap between the US and emerging markets regarding mobile payments.” HUMBL has designed a mobile wallet (HUMBL®) and merchant software (HUMBL Hubs™), that help primarily cash economies migrate to digital money services across key vertical markets, such as: government, banking, wireless carriers and merchant services. HUMBL’s global money platform will deliver up to 50% estimated savings on transactions such as: sending, receiving, lending, borrowing, investing money and paying bills.  

Microcapdaily was among the first on the scene when TSNP started moving northbound reporting on TSNP on November 15, 2020 when the stock was $0.003 stating at the time: “Tesoro Enterprises, Inc. (OTCMKTS: TSNP) is making a spectacular run up the charts in recent weeks quickly transforming into a volume leader and one of the top most traded stocks in small caps. TSNP started off in triple zero land but has gone parabolic since than quickly attracting legions of new shareholders who continue to bid the stock higher. Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotech’s in their ability to make historic gains. TSNP is the perfect merger candidate; a clean shell with virtually no debt and the new Company HUMBL is a major mobile payments player with a first-class management team with team members coming from companies like Western Union, Moneygram, Visa, American Express, Epson, Microsoft, Facebook and Qualcomm and was recently named a Forbes “Rising Startups to Watch” The whole deal is being shepherded by George Sharp, a reverse merger whizz and someone known for doing it right.   

HUMBL is led by CEO Brian Foote who is well known in the crypto community and brings with him twenty years of consumer technology experience, having launched a number of top ranked global technology products at companies like Epson, where he was twice named to the Innovators Team Award for his work across merchant partners such as Amazon, Walmart, Costco, Target and Best Buy. In recent months Brian Foote has reduced the share count by at least 800 million and pledged not to dilute the stock in the future.   

HMBL has also brought Mr. George Sharp back as Capital Markets Advisor. Mr. Sharp will shepherd HUMBL through an imminent application with OTC Markets for an advancement to the OTCQB tier and then towards an application to the NASDAQ Stock Market. In furtherance of these milestones, the company will file audited financials with the SEC beginning with the yearend statement for 2021.  

To get an inside look at HUMBL Subscribe to Microcapdaily.com immediately by entering your Email below

HMBL

On November 23 HMBL announced the newest release of the “HUMBL Pay” mobile wallet, including the latest upgrades to its Peer-to-Peer (P2P) functionalities, and additional features that simplify the management of digital assets and blockchain functionality. Under this release, which is now available on the Apple App Store and Google Play Store, HUMBL Pay users can: 

  • – Buy digital assets via major credit cards inside the HUMBL Pay mobile wallet 
  • – Send digital assets such as BTC, ETH and USDC between HUMBL mobile wallets 
  • – Perform gasless digital asset transactions between HUMBL mobile wallets 
  • – Earn as much as 7% interest on various digital assets 

The HUMBL Pay mobile wallet accommodates the purchase of digital assets by credit card, as well as the send and receipt of such digital assets from other users of the HUMBL Pay mobile wallet. Now, the HUMBL Pay user can perform gasless P2P transactions across various digital assets such as Bitcoin, Ethereum and USDC (US Dollar Stablecoin). The HUMBL technology team is also working to accommodate P2P transactions across major government-issued fiat currencies, such as the US Dollar (USD) and additional blockchain-authenticated integrations. Additional HUMBL Pay features now under development include the importing of contact lists to HUMBL Pay, ACH onboarding, BLOCK ETX integrations and the addition of other digital assets such as BLOCKS to the HUMBL Pay mobile wallet. 

“Our mission for the HUMBL Pay wallet is to create simple, blockchain pathways for global consumers. We have now achieved another key milestone on that path,” stated HUMBL President and CEO, Brian Foote. “The HUMBL Pay mobile wallet now offers the purchase of digital assets such as Bitcoin and Ethereum, frictionless P2P transactions through USDC Stablecoin, and higher APY interest rates than the majority of global banks through DeFi solutions.” 

For More on HUMBL Subscribe Right Now!

HMBL is coiled tight trading just over established support levels on heavy interest trading $2.3 million in dollar volume on Wednesday alone; a slow day for Humbl. The stock has huge support from investors and a massive following who see big things happening here. The Company continues to make progress recently releasing the newest release of the “HUMBL Pay” mobile wallet, including the latest upgrades to its Peer-to-Peer (P2P) functionalities, and additional features that simplify the management of digital assets and blockchain functionality. The release is now available on the Apple App Store and Google Play Store.  HMBL recently brought back George Sharp as Capital Markets Advisor. Mr. Sharp will shepherd HUMBL through an imminent application with OTC Markets for an advancement to the OTCQB tier and then towards an application to the NASDAQ Stock Market. In furtherance of these milestones, the company will file audited financials with the SEC beginning with the yearend statement for 2021. HMBL was one of the biggest runners of early 2021 when the stock skyrocketed shortly after the name and ticker symbol change from TSNP. George Sharp is a stock whizz with anything he touched turning to gold and HMBL was the biggest runner of them all going from sub pennies to multi dollars. There are plenty of coming catalysts including the next App updates, NFT, Tickeri, music beta test and the anticipated coming OTCQB uplist. We will be updating on HMBL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HMBL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HMBL either long or short and we have not been compensated for this article.

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.